Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$138.51M

FY 2025 · Annual

Investing Cash Flow

$375.09M

FY 2025 · Annual

+62.9% YoY

Financing Cash Flow

-$273.70M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(287.1M)(291.75M)(237.89M)28.51M168.02M
Depreciation & Amortization3.45M3.7M3.79M5.28M3.92M
Deferred Income Tax9.44M0000
Stock-Based Compensation51.36M50.74M43.11M27.8M16.97M
Change in Working Capital42.36M(79.26M)(36.83M)55.89M(5.84M)
Accounts Receivables34.06M13.05M(150.68M)149.35M93.56M
Inventory(6.25M)(47.35M)(46.73M)(31.95M)(17.11M)
Accounts Payables874K(4.55M)23.76M(3.94M)(19.56M)
Other Working Capital13.68M(40.41M)136.83M(57.57M)(62.74M)
Other Non-Cash Items143.05M75.45M52.93M(137.92M)(321.59M)
Operating Cash Flow(37.43M)(241.12M)(174.88M)(20.44M)(138.51M)
Capital Expenditures(1.29M)(2.04M)(286K)00
Acquisitions (Net)1.29M0845K00
Purchases of Investments(182.49M)(127.38M)(19.51M)0(103.84M)
Sales of Investments181.36M0157.64M14.89M21.46M
Other Investing Activities(137.29M)(37.43M)5.95M215.43M457.46M
Investing Cash Flow(138.41M)(166.85M)144.64M230.32M375.09M
Debt Repayment(672K)49.93M0(223.41M)(233.19M)
Common Stock Issued40.9M6.36M74.22M1.46M8.25M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities54.3M(1.96M)(4.62M)34.98M(48.77M)
Financing Cash Flow51.88M54.33M69.6M(186.97M)(273.71M)
Effect of Forex Changes00(12K)00
Net Change in Cash(123.96M)(353.65M)39.34M22.91M(37.13M)
Free Cash Flow(38.72M)(243.16M)(175.17M)(20.44M)(138.51M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$168.0M
+ D&A$3.9M
+ Stock-Based Comp$17.0M
+ Deferred Tax$0
- Working Capital-$5.8M
- Other Non-Cash-$321.6M
= Operating Cash Flow-$138.5M
- Capex$0
= Free Cash Flow-$138.5M

Analysis

FY2025 free cash flow is -$138.5M. FCF conversion is -82.4% of net income. Operating cash flow was -$138.5M, with capex of $0. The largest bridge item is Other Non-Cash at -$321.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportOct 29, 2026
8-KCurrent reportAug 28, 2026
424B5424B5 filingAug 28, 2026

Does CHRS generate free cash flow?

Coherus Oncology, Inc. (CHRS) generated -$138.51M of free cash flow in fiscal 2025.

How much operating cash flow does CHRS produce?

Operating cash flow was -$138.51M, before capital expenditures of $0.00.